People: Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

21 Aug 2018
Change (% chg)

$-0.31 (-8.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hirsch, Gordon 

Dr. Gordon Hirsch is the Chief Medical Officer of the Company. Dr Hirsch has spent almost twenty years in the pharmaceutical industry where he has worked with Pfizer Inc (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Sanofi SA (NYSE: SNY), and The Takeda Pharmaceutical Company (TYO: 4502). His career has involved a broad range of global responsibilities, stretching from early development to commercialisation, and including appointments in Australia, Japan, France, and the United States, and encompassing a portfolio of products with global sales in the billions of dollars. He holds a medical degree from the University of the Witwatersrand in South Africa, and an MBA from Henley Business College in the UK. Dr Hirsch will be based in Sydney, Australia.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --